Alnylam’s Trading Volume Surges 38.6% to Rank 113th in Market Activity

On August 13, 2025, Alnylam Pharmaceuticals (ALNY) recorded a trading volume of $0.90 billion, marking a 38.63% increase from the previous day and ranking 113th in market activity. The stock closed up 0.60% for the session.

Recent developments highlight mixed institutional activity and analyst sentiment. ProShare Advisors LLC reduced its stake by 3,227 shares, while Duality Advisers LP acquired 2,051 shares. DnB Asset Management AS increased its holdings, and Sanders Morris Harris LLC allocated $664,000 to ALNY. Analyst ratings remain varied, with HC Wainwright reiterating its positive outlook, Stifel Nicolaus maintaining a "Buy" rating, and Cantor Fitzgerald adopting a "Neutral" stance. Meanwhile, New York State Common Retirement Fund and Axa S.A. trimmed their positions.

Regulatory updates remain pivotal. An FDA advisory committee endorsed Alnylam’s gene-silencing therapy for expanded use in rare heart disease despite concerns over efficacy. However, potential label restrictions for Patisiran persist ahead of final approval. Positive phase 2 results from the KARDIA-1 study for zilebesiran, which met primary endpoints in hypertension treatment, further bolstered investor confidence.

The strategy of purchasing the top 500 stocks based on daily trading volume and holding them for one day from 2022 to the present has yielded moderate returns. The total profit increased steadily over the period, with minor fluctuations influenced by market dynamics. At the conclusion of the simulation, the strategy achieved a 20.15% gain, demonstrating a strong long-term performance driven by high daily trading volumes.